Webinar

Abstract:

Antibody-drug conjugates (ADC) are complex therapeutics with multiple components, all of which require specialized teams of scientists. The field has evolved significantly over that last decade as lessons learned and novel innovations have led to increased clinical success. Yet, as more innovators join in the search for cures, competition increases as companies chase first-to-market milestones and best-in-class therapeutic status. Increasingly and to gain traction quickly, innovators look to outsource one or more aspects of production across the complex supply chain. However, the choices in outsourcing have their own challenges.

In this webinar, we will discuss ADC therapeutic market trends and technology advancements and how those trends relate and impact the selection of the optimal development and production partner.

Participants Will Learn:

• How to simplify the ADC production supply chain
• Value of optimizing the drug-to-antibody ratio (DAR)
• Why experience in toxin and linker production will accelerate projects
• Advantages of a single-source supplier

Speakers:

• Lily Yin, Executive Director, Head of Biologics Conjugation Development, WuXi Biologics
• Ying Buechler, Ph.D., Vice President of Development, Ambrx
• Youchu Wang, Ph.D., Vice President, Process R&D, WuXi STA
• Alexandra Taylor, Associate Editor, C&EN

View Recording